Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Provided By GlobeNewswire
Last update: Apr 9, 2025
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody
CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025
Read more at globenewswire.comNASDAQ:CNTX (11/20/2025, 2:48:03 PM)
1.13
-0.04 (-3.42%)
Find more stocks in the Stock Screener
